3rd International Conference on Chronic Obstructive Pulmonary Disease Jul 11, 2016 20160711 Jul 12, 2016 Park Regis North Quay, 293 North Quay, Brisbane 4000, Australia COPD 2016 will explore thought-provoking topics and recent research in the field of lung related issues. COPD 2016 is a trending conference which brings together academic scientists, specialists and young researchers, creating a perfect platform for participants to gain experience and evaluate emerging technologies through discussing recent advancements in COPD. Initiation of cross-border coordination between scientists and institutions will be also facilitated.  International symposiums, B2B meetings and international workshops will also be organized to discuss the specific topics in the field of Chronic Obstructive Pulmonary Disease. /content/dam/pmiscience/default-fallback-thumbnails/conference/phillip-morris-science-detail-background.png

      3rd International Conference on Chronic Obstructive Pulmonary Disease

      Date
      Jul 11, 2016 - Jul 12, 2016
      Location
      Park Regis North Quay, 293 North Quay, Brisbane 4000, Australia
      COPD 2016 will explore thought-provoking topics and recent research in the field of lung related issues. COPD 2016 is a trending conference which brings together academic scientists, specialists and young researchers, creating a perfect platform for participants to gain experience and evaluate emerging technologies through discussing recent advancements in COPD. Initiation of cross-border coordination between scientists and institutions will be also facilitated.  International symposiums, B2B meetings and international workshops will also be organized to discuss the specific topics in the field of Chronic Obstructive Pulmonary Disease.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.